---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-084062"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:38:38.630731+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pasithea shareholders approve reverse split authorization (1:2–1:20) and 1.75M share increase for equity plan

## Summary
- Stockholders approved reverse stock split of common stock at ratio from 1:2 to 1:20, at Board discretion, valid through September 2026.
- Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares by 1.75M to 2,014,221 shares.
- Ratified CBIZ CPAs P.C. as independent auditor for FY2025 with 3.40M for, 39K against, 52K abstain.
- Re-elected Alfred Novak (1.31M for) and Simon Dumesnil (1.29M for) as Class II directors, terms expiring 2028.
- Quorum of 3.5M of 7.4M outstanding shares represented at the meeting; no other business.

## SEC filing metadata
- accession: 0001213900-25-084062
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390025084062/0001213900-25-084062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390025084062/ea0255742-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-084062
- JSON: https://secwatch.observer/filing/0001213900-25-084062.json
- Plain text: https://secwatch.observer/filing/0001213900-25-084062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.